Comparing Direct TAVR to Balloon Aortic Valvuloplasty-TAVR in Patients with Cardiogenic Shock and Severe Aortic Stenosis—A TriNetX-Based Study
Journal of Clinical Medicine · 25.06.2026 · 15 (13) · 4943
DOI: 10.3390/jcm15134943 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 25.06.2026. Verfasst von Aditya Desai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of California, Riverside School of Medicine, Riverside, CA 92521, USA. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
Severe aortic stenosis (AS) with cardiogenic shock (CS) presents a complex clinical challenge. For these patients, the optimal management strategy—either direct transcatheter aortic valve replacement (TAVR) or a staged approach with balloon aortic valvuloplasty (BAV) as a bridge to TAVR (BAV-TAVR)—is uncertain. We aimed to compare the outcomes of these two strategies.
Methods
We conducted a retrospective cohort study using the TriNetX database. In this study, we identified patients with CS who underwent direct TAVR or who survived to and underwent TAVR within 30 days of balloon aortic valvuloplasty (BAV-TAVR). After matching propensity scores, 198 patients were analyzed in each group (total of 396). The primary outcome was major adverse cardiovascular events (MACE) at 30 days, 1 year, and 3 years.
Results
The analysis included 396 matched patients (198 in each cohort). There was no significant difference in the primary endpoint of MACE at 30 days between the staged BAV and direct TAVR groups HR 1.14 (95% CI 0.79–1.64; p = 0.48), and this finding was consistent at 1 and 3 years with HR 1.20 (95% CI 0.89–1.61; p = 0.23) and HR 1.17 (95% CI 0.89–1.53; p = 0.25) respectively. Similarly, no differences were observed in secondary outcomes including all-cause mortality, stroke, and new permanent pacemaker implantation, at 30 days, 1, and 3 years.
Conclusions
Among patients with severe AS and cardiogenic shock who survived definitive therapy, staged BAV-TAVR showed no detectable difference in short- or long-term outcomes versus direct TAVR. Given the limited sample size and the exclusion of patients who did not survive to TAVR, these results are hypothesis-generating and should not be read as evidence of equivalence or of bridging safety; prospective study is warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, University of California, Riverside School of Medicine, Riverside, CA 92521, USA.
- Department of Internal Medicine, Hurley Medical Center, Michigan State University of Human Medicine, Flint, MI 48824, USA.
- Division of Cardiology, University of New Mexico, Albuquerque, NM 87106, USA.
ORCID-Profile: Simran Gill, Haresh Gandhi, Tanawan Riangwiwat
Zitieren
APA
Desai, A., Gill, S., Manoj, A., Mandal, N., Hajeh, H., Desai, D., Gandhi, H., Sethi, P., Blankenship, J., & Riangwiwat, T. (2026). Comparing Direct TAVR to Balloon Aortic Valvuloplasty-TAVR in Patients with Cardiogenic Shock and Severe Aortic Stenosis—A TriNetX-Based Study. Journal of Clinical Medicine, 15(13), 4943. https://doi.org/10.3390/jcm15134943
Vancouver
Desai A, Gill S, Manoj A, Mandal N, Hajeh H, Desai D, et al. Comparing Direct TAVR to Balloon Aortic Valvuloplasty-TAVR in Patients with Cardiogenic Shock and Severe Aortic Stenosis—A TriNetX-Based Study. Journal of Clinical Medicine. 2026;15(13):4943. doi:10.3390/jcm15134943
BibTeX
@article{Desai2026,
author = {Desai, Aditya and Gill, Simran and Manoj, Aparna and Mandal, Naishal and Hajeh, Haidar and Desai, Darshi and Gandhi, Haresh and Sethi, Prabhdeep and Blankenship, James and Riangwiwat, Tanawan},
title = {Comparing Direct TAVR to Balloon Aortic Valvuloplasty-TAVR in Patients with Cardiogenic Shock and Severe Aortic Stenosis—A TriNetX-Based Study},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {13},
pages = {4943},
doi = {10.3390/jcm15134943}
}
EUVIMED